RNAC
Price
$9.67
Change
+$0.25 (+2.65%)
Updated
Oct 15, 11:11 AM (EDT)
Capitalization
244.94M
Intraday Buy/Sell Signals
XOMAP
Price
$26.25
Change
+$0.06 (+0.23%)
Updated
Oct 14, 01:58 PM (EDT)
Capitalization
N/A
Intraday Buy/Sell Signals
Interact to see
Advertisement

RNAC vs XOMAP

Header iconRNAC vs XOMAP Comparison
Open Charts RNAC vs XOMAPBanner chart's image
Cartesian Therapeutics
Price$9.67
Change+$0.25 (+2.65%)
Volume$400
Capitalization244.94M
XOMA
Price$26.25
Change+$0.06 (+0.23%)
VolumeN/A
CapitalizationN/A
RNAC vs XOMAP Comparison Chart in %
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RNAC vs. XOMAP commentary
Oct 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RNAC is a Hold and XOMAP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 17, 2025
Stock price -- (RNAC: $9.42 vs. XOMAP: $26.19)
Brand notoriety: RNAC and XOMAP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RNAC: 103% vs. XOMAP: 87%
Market capitalization -- RNAC: $244.94M vs. XOMAP: $0
RNAC [@Biotechnology] is valued at $244.94M. XOMAP’s [@Biotechnology] market capitalization is $0. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RNAC’s FA Score shows that 0 FA rating(s) are green whileXOMAP’s FA Score has 1 green FA rating(s).

  • RNAC’s FA Score: 0 green, 5 red.
  • XOMAP’s FA Score: 1 green, 4 red.
According to our system of comparison, XOMAP is a better buy in the long-term than RNAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RNAC’s TA Score shows that 4 TA indicator(s) are bullish while XOMAP’s TA Score has 4 bullish TA indicator(s).

  • RNAC’s TA Score: 4 bullish, 4 bearish.
  • XOMAP’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both RNAC and XOMAP are a good buy in the short-term.

Price Growth

RNAC (@Biotechnology) experienced а -3.29% price change this week, while XOMAP (@Biotechnology) price change was +0.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.44%. For the same industry, the average monthly price growth was +17.42%, and the average quarterly price growth was +81.94%.

Industries' Descriptions

@Biotechnology (+0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XOMAP YTD gains are higher at: 10.005 vs. RNAC (-47.404). XOMAP has higher annual earnings (EBITDA): -305K vs. RNAC (-118.73M). RNAC has more cash in the bank: 160M vs. XOMAP (93.3M). RNAC has less debt than XOMAP: RNAC (13.3M) vs XOMAP (115M). XOMAP has higher revenues than RNAC: XOMAP (12.8M) vs RNAC (1.03M).
RNACXOMAPRNAC / XOMAP
Capitalization245MN/A-
EBITDA-118.73M-305K38,928%
Gain YTD-47.40410.005-474%
P/E Ratio1.98N/A-
Revenue1.03M12.8M8%
Total Cash160M93.3M171%
Total Debt13.3M115M12%
FUNDAMENTALS RATINGS
RNAC: Fundamental Ratings
RNAC
OUTLOOK RATING
1..100
6
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
87
P/E GROWTH RATING
1..100
42
SEASONALITY SCORE
1..100
47

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RNACXOMAP
RSI
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 7 days ago
16%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
12%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
29%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
23%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
28%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
28%
Advances
ODDS (%)
Bullish Trend 15 days ago
82%
Bullish Trend 4 days ago
24%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 10 days ago
18%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
6%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
22%
View a ticker or compare two or three
Interact to see
Advertisement
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BMRC24.241.09
+4.71%
Bank of Marin Bancorp
SYM73.643.13
+4.44%
Symbotic
CENTA26.720.45
+1.71%
Central Garden & Pet Company
FGBIP19.270.02
+0.10%
First Guaranty Bancshares
NSTS11.35N/A
N/A
NSTS Bancorp

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-0.79%
TAOX - RNAC
91%
Closely correlated
+0.63%
ALLR - RNAC
86%
Closely correlated
-1.63%
NRXP - RNAC
86%
Closely correlated
-2.24%
PALI - RNAC
81%
Closely correlated
-0.54%
OCUL - RNAC
48%
Loosely correlated
-5.40%
More

XOMAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, XOMAP has been loosely correlated with AMLX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if XOMAP jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XOMAP
1D Price
Change %
XOMAP100%
N/A
AMLX - XOMAP
51%
Loosely correlated
+0.57%
CGEN - XOMAP
31%
Poorly correlated
-5.36%
RNAC - XOMAP
29%
Poorly correlated
-0.79%
XOMAO - XOMAP
27%
Poorly correlated
-0.32%
MGTX - XOMAP
26%
Poorly correlated
+1.28%
More